TLR9 and neoplasm: In contrast to the spleen, in tumor tissues, the combined effects of STING and TLR9 agonists resulted in an approximately 70-fold increase in IFN-β expression compared with the control group, which is a remarkable finding and indicates the pro-inflammatory status in the TME (Figures 2A, 3A).